Metagenomi, Inc. is advancing its proprietary genome editing platform supported by a strategic lipid nanoparticle delivery license, focusing on preclinical product candidates without clinical-stage revenues. Operating losses deepened in 2025 alongside continued cash burn, though operating cash flow slightly improved due to cost management and streamlined capital expenditures. The company faces funding necessities to sustain research momentum amid regulatory complexities and intense competition. Key near-term milestones include regulatory filings that will signal the transition toward clinical development and commercial viability.